Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Hepion Pharmaceuticals, Inc. (HEPA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5200-0.0200 (-1.30%)
At close: 4:00PM EDT
1.5400 +0.02 (+1.32%)
After hours: 07:47PM EDT
Advertisement
Sign in to post a message.
  • P
    PharmaExpert
    $ALT conversation
    Go long on **CALA** into Q4 and add dips , this stock will move.... consolidated for 6 months and huge catalysts ahead and good Institutions loading

    -CB-280- Cystic fibrosis - Phase 1b interim data- 4Q 2021

    -Telaglenastat (CB-839) - KEAPSAKE Non-small cell lung cancer (NSCLC) patients with genetic mutation NRF2/KEAP - Phase 2 interim data due 4Q 2021.

    -Mark Lampert’s Biotechnology Value Fund L P has 10.10% stake here ; interesting he wanted 10%+ ownership to be a Major Shareholder before data

    BVF disclosed ownership of 7,452,331 shares in July an increase of 70% from their February 2021 filing

    BVF was the main institution behind the $FPRX turnaround last year which went from $4s ~> $38 in a $1.9B Buyout by Amgen after a bidding war

    $PGEN $JNCE $CASI $HEPA $AGTC
    Bullish
  • b
    bourbon_on_my_cornflakes
    HEPA stock basically selling for cash on the balance sheet despite good p2 results? Shareholders vtoing against mgt? Stock looks super cheap but what part of the story am I missing?
  • J
    Jamie
    Looks like shareholders voted against increasing number of shares from 120k to 240k, as well as management incentives and pay. Maybe this will be a wake-up call.
  • L
    LurkerInvestor
    Nice presentation from Hobbs
  • A
    Andrew
    I'm betting very heavily (commons and calls) that we see double digits before the year is out
  • A
    Arts,Food&Business
    Vote NO and HOLD
    Bullish
  • A
    Arts,Food&Business
    New PR for Hepa
    Bullish
  • S
    Sam A
    Interview with Dr. Foster in May of this year.

    https://www.youtube.com/watch?v=K-8I_O-KU74
    Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster
    www.youtube.com
  • S
    Sam A
    Dr. Robert Foster Profile - Aurinia Pharmaceuticals/Hepion Pharmaceuticals
    www.youtube.com
  • S
    Sam A
    Floki. Contravir Pharmaceuticals worked on FV-100 to treat herpes Zoster and post herpetic neuralia and CMX157 to treat Hepatitis B. In 2016 company acquired Ciclofilin from Dr. Foster which worked with Ciclofilin inhibitors to treat liver diseases. In October 2018 Dr. Foster became CEO and in July 2019 the name changed to Hepion. For past three years HEPA has hired great people and their Phase 2a trial went very well in fact showed better results for such a short time compared to other company trials. The market for NASH is big $30 to $50 billion just in the U.S. alone. Phase 2b which whill start soon has a larger pool of patients and will focus on fibrosis biomarkers. In Phase 2b this company will use AI POWR to identify which patients will benefit from their drug. I believe the results will be good so we must wait and see and when it happens within next 18 months the stock will be much higher.
  • M
    Michael
    oh no ......good news..... down it goes
    Bullish
  • E
    Erkan
    I think this week it is going up to 2,00
  • T
    TM
    lots of insider buys in past year
  • R
    Richard
    How much do you expect stock prices to rise on Monday?
    Bullish
  • E
    Edmund
    SA Bullish article is out:

    "The next two catalysts are very close: Publication of the complete results of the Phase IIa trial (expected this September), and the start of the Phase IIb trial for next Q4."
  • R
    Ryan
    Easy $5 soon.. not many know
  • B
    Bertil
    I think the problem here is Dilution still from the last offering and on top of that they want to add 200mil more shares. Whats This CFO Doing???
  • A
    Abel David
    ⏳📈💰 I.S.T. NEWS ALERT
    👉 $HEPA Hepion Pharmaceuticals, Inc. is scheduled to release additional data from its Phase 2a ‘AMBITION' NASH clinical trial of CRV431 before the market opens Monday, Sept. 13,
    Bullish
Advertisement
Advertisement